EP1.14-34 Advanced NSCLC Treated with Gefitinib or Erlotinib for Five Years or Longer - Updated Data from the Retrospective Slovakian Study

Autor:	M. Vesela, A. Cipkova, I. Jancokova, Gabriela Chowaniecova, J. Mazal, P. Berzinec, Lukáš Plank, Peter Kasan, Iveta Kuliskova, M. Martak, I. Andrasina, M. Urda
Rok vydání:	2019
Předmět:	Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty Gefitinib business.industry Internal medicine Medicine Erlotinib business medicine.drug
Zdroj:	Journal of Thoracic Oncology. 14:S1045
ISSN:	1556-0864
DOI:	10.1016/j.jtho.2019.08.2319
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3b9b24f42f2a598594cda43f0fdce7c9 https://doi.org/10.1016/j.jtho.2019.08.2319 Zobrazit plný text záznamu